Matthew Lang was named Chief Operating Officer of Structure Therapeutics Inc., effective April 15, 2026. As of November 6, 2026, Structure Therapeutics Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 15, 2026, naming 1 appointment (Form 8-K, April 15, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Structure Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Structure Therapeutics Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-15. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Structure Therapeutics Inc. files it.
Also on the record for Structure Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 13.2% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 4.9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 5.95% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 10.1% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by Avoro Capital Advisors LLC | 9.38% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 7.32% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 7.7% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 11.9% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 9.9% of the class | 5%+ stakes | Source |
| August 18, 2025 | Stake report, Schedule 13G, by BVF PARTNERS L P/IL | 5.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Structure Therapeutics Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Structure Therapeutics Inc. and the records around it.
Structure Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Watch Structure Therapeutics Inc.
Get an email when Structure Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Structure Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Structure Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Structure Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 16 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-15 | In | Chief Operating Officer | 2026-04-15 | 8-K, 2026-04-15 |
Who leads Structure Therapeutics Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Operating Officer: Matthew Lang, appointed, effective 2026-04-15 (filed 2026-04-15).
New leaders reset buying decisions — get the Full Report on Structure Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Operating Officer at Structure Therapeutics Inc., with the record behind each one.
Find candidates like Chief Operating Officer at Structure Therapeutics Inc.Every change, in the filing's words
Appointed: Matthew Lang, Chief Operating Officer, effective 2026-04-15
Matthew Lang was appointed as Structure Therapeutics, Inc.'s (the "Company") Chief Operating Officer and General Counsel, effective April 15, 2026.
- Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- Mr. Lang previously served as the Chief Legal Officer and Corporate Secretary at Metsera, Inc. ("Metsera"), a biopharmaceutical company, from April 2025 until February 2026 and prior to Metsera Mr. Lang served as Chief Business Officer and Chief Legal Officer and Corporate Secretary of Lyell Immunopharma, Inc. ("Lyell"), a biotechnology company, from July 2023 to April 2025.
- Before joining Lyell, Mr. Lang held several executive officer positions at Myovant Sciences, Inc. ("Myovant"), a biotechnology company, between 2017 and 2023, most recently as Chief Administrative and Legal Officer.
- Mr. Lang also served as Managing Director and General Manager of Myovant Sciences GmbH in Basel, Switzerland.
- Mr. Lang previously held leadership positions at Gilead Sciences, Inc. ("Gilead"), from November 2009 to July 2017, most recently as Vice President, Head of Global Litigation, Investigations, Employment Law and Information Governance.
- Prior to Gilead, from 2003 to 2009, Mr. Lang was an attorney at Dechert LLP.
- Mr. Lang received his B.A. in Classical Studies from Queen's University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School.
Tools for this story
Each opens in a new tab, filled in for Structure Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.